Clinical trial
A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis…
NCT00434278 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00434278 |
|---|---|
| Title | A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC) |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Dornase alfa, placebo |
| Enrollment | 27 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 13, 2007 |
| Last update posted | May 16, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: